Article Text

Download PDFPDF
Original article
Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications
  1. Francis L Munier1,
  2. Marie-Claire Gaillard1,
  3. Aubin Balmer1,
  4. Sameh Soliman1,2,
  5. Gregory Podilsky3,
  6. Alexandre P Moulin1,
  7. Maja Beck-Popovic4
  1. 1Unit of Pediatric Ocular Oncology, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
  2. 2Department of Ophthalmology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
  3. 3Central Pharmacy, University Hospital CHUV, Lausanne, Switzerland
  4. 4Unit of Pediatric Hematology-Oncology, University Hospital CHUV, Lausanne, Switzerland
  1. Correspondence to Professor Francis L Munier, Unit of Pediatric Ocular Oncology, Jules-Gonin Eye Hospital, University of Lausanne, Avenue de France 15, Lausanne 1004, Switzerland; francis.munier{at}


Background Tumour control of vitreous seeds remains challenging owing to their resistance to radiation and systemic chemotherapy.

Objective To describe the short-term efficacy of intravitreal melphalan for vitreous disease in retinoblastoma using a new injection technique and dose.

Methods This study is a retrospective non-comparative review of 23 consecutive heavily pretreated patients (23 eyes) with active vitreous seeding and eligible for intravitreous chemotherapy (IViC). They received a total of 122 intravitreal injections of melphalan (20–30 μg) given every 7–10 days. The ocular status was objectively monitored under anaesthesia with fundus photography.

Results All patients are alive without evidence of extraocular spread (95% CI 82.19% to 100%). Concomitant treatments, including other chemotherapeutic modalities, were used until complete sterilisation of the retinal seeding source and subretinal seeds. Globe retention was achieved in 87% (20/23) of cases. All retained eyes were in complete remission after a median follow-up period of 22 months (range 9–31 months). The Kaplan–Meier estimate of ocular survival rates at 2 years was 84.14% (95% CI 62.48% to 95.28%). A localised peripheral salt-and-pepper retinopathy was noted in 10 eyes (43%) at the site of injection.

Conclusions This study reports the first clinically documented case series of patients with retinoblastoma treated with IViC. Despite a possible confounding effect of concomitant chemotherapy prescription using other routes of administration in four of the successfully treated eyes (20%), IViC achieved an unprecedented success rate of tumour control in the presence of vitreous seeding. Of note, none of the treated eyes required external beam irradiation to control the vitreous seeding. Further studies are required to assess IViC retinal toxicity and to better delineate its role in the management of retinoblastoma.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Linked articles 301016.

  • Presented in part as “Retinoblastoma Keynote Lecture” at the XVth Biannual Meeting of the International Society of Ocular Oncology, Buenos Aires, Argentina, 14–17 November 2011

  • Funding This study was supported by a grant from the Foundation Conteurs San Frontières.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by Comité d'Ethique Cantonale.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles